6505--Hydralazine HCL Tablets Effective 04/08/2026 to 04/07/2027

The Department of Veterans Affairs National Acquisition Center awarded contract 36E79726D0013 to Radha Pharmaceuticals Inc. for the supply of Hydralazine HCL Tablets. The award, valued at 7,450,452.60 dollars, covers a performance period from April 8, 2026, to April 7, 2027. This procurement was conducted as an unrestricted, firm-fixed-price, indefinite-delivery requirements contract under NAICS code 325412. The contract provides pharmaceuticals for the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service, with distribution managed through Pharmaceutical Prime Vendor Programs. The scope of the award includes seven line items for Hydralazine HCL tablets in various strengths (10mg, 25mg, 50mg, and 100mg) and bottle sizes (100 and 1000 count). The contract structure consists of a one-year base period with four optional one-year extensions. Technical requirements mandate strict adherence to FDA cGMP compliance, the use of unique 11-digit National Drug Codes, and specific packaging standards that prohibit glass bottles and require child-resistant caps for smaller containers. Administration of the contract involves a non-standard payment flow where the contractor is paid by Pharmaceutical Prime Vendor contractors, such as McKesson Corporation and Cencora, rather than directly by the government. Consequently, the contractor is prohibited from invoicing government facilities and must maintain binding business-to-business agreements with the designated prime vendors. Award was based on the Lowest Price Technically Acceptable (LPTA) evaluation method, ensuring all technical and FDA regulatory thresholds were met before price became the deciding factor.